Shots:
Innovent Biologics has entered into an exclusive agreement with Daiichi Sankyo to commercialize Vanflyta (quizartinib) in China
As per the deal, Daiichi Sankyo will handle the development, manufacturing & supply of Vanflyta while Innovent will hold sole commercialization rights for Vanflyta in China
Vanflyta was approved in China in Jun’26 for newly diagnosed FLT3-ITD-positive AML in…
